AI assistant
Sending…
Actinium Pharmaceuticals, Inc. — Director's Dealing 2018
Jul 17, 2018
34570_dirs_2018-07-17_a8d1372e-d346-410c-875f-0a1239b67a5e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2018-07-13
Reporting Person: Nicholson, C. David (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-07-13 | Options to purchase common stock | $0.7829 | A | 75000 | Acquired | 2028-07-13 | Common Stock (75000) | Direct |
Footnotes
F1: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant.
More from Actinium Pharmaceuticals, Inc.
Regulatory Filings
2026
May 29
Annual Report
2026
Mar 30
Regulatory Filings
2026
Mar 26
Regulatory Filings
2026
Feb 13
Regulatory Filings
2025
Nov 26
Interim / Quarterly Report
2025
Nov 14
Annual Report
2025
Nov 5
Proxy Solicitation & Information Statement
2025
Nov 5
Director's Dealing
2025
Aug 20
Interim / Quarterly Report
2025
Aug 8